COLLEYVILLE, TX--(Marketwire - April 17, 2008) - digiMedical Solutions, Inc. (PINKSHEETS: DGMS) announced today that the Company has signed a contract with Dr. Yovanni Tineo in Naples, Florida, to implement the digiRX system and digiReauth call center services. digiRX and digiReauth are both proprietary, Microsoft-based applications developed by digiMedical that provide digital prescription handling for physicians, including prescription reauthorization processing and refill management services.

Dr. Tineo, who has more than 5,000 patients, received her doctorate from New York College of Osteopathic Medicine (NYCOM) of New York Institute of Technology in Old Westbury, NY and completed her residency at Jamaica Hospital in Queens, NY.

Contract Follows Multiple Other Contracts in the Naples Area Increasing Company's Regional Footprint

The Company is actively expanding their regional footprint in the Naples area in support of the 2008 revenue goal of $10 million. Each new doctor contract can add hundreds of patients to the digiRX network, who in turn drive prescription sales in company owned pharmacies and increase company revenue.

This contract follows digiMedical's recent announcements of other contracts with Orthopedic Surgeon Dr. Howard Kapp of Anchor Health Centers, Drs. Santos-Ocampo, Axline and Spilker of the Collier Heart Group, the Medical Director of Vanish Vein and Laser Center and Dr. Wey of the Neuroscience and Spine Associates in Naples, Florida.

digiMedical Prescription Handling Software and Pharmacies

digiMedical Solutions, a Microsoft Partner, with operations in Texas and Florida, has built its own suite of proprietary software to handle prescriptions digitally from the physician's office to the pharmacy, securely and in compliance with all DEA and HIPAA requirements. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and now digiAccounting and the Company owns and operates five pharmacies throughout Texas and Florida.

Recent Analyst Report Coverage with Recommendation of $0.30 or Higher

Micros Report initiated research coverage of digiMedical Solutions and issued a report reviewing the Company's historical operations and 2008 business plan. Michael Willingham, Micros Report Director of Research, authored the report which includes a Fair Value Target price for DGMS of $0.30.

In the report, Mr. Willingham stated, "digiMedical's proprietary technology solution positions the company to profit from both the traditional existing pharmacy market space and the future of digital prescription fulfillment."

The report is available at under "Featured Presentation." Interested parties may also access the report by going to the homepage or by emailing and requesting a copy.

Company Information and Updates

To be added to digiMedical's corporate e-mail list for shareholders and interested investors or to receive more information on the company, please send an e-mail to

About digiMedical Solutions, Inc.™

digiMedical Solutions, Inc.™ ( is a pharmacy and medical technology company focused on developing next generation digital medical technology with an emphasis on digital prescriptions (d-Prescriptions) that will more closely align the doctor, pharmacist and patient. The company's planned growth will come from three channels: direct marketing of the company's wireless base d-prescription technology to doctors, acquisition of independent pharmacy chains and the sale of certain territories to "market partners" licensed to exploit the digiMedical Solutions™ model. digiMedical Solutions, Inc.™ currently owns and operates five (5) pharmacies located in Texas and Florida. digiMedical Solutions'™ unique business model brings doctor, patients and pharmacies into next generation medical technologies.

Forward-Looking Statement

Statements included in this press release which are not historical in nature, are intended to be, and are hereby identified as "Forward-Looking Statements" for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements may be identified by words including "anticipate," "await," "envision," "foresee," "aim at," "believe," "intends," "estimates" including without limitation, those relating to the company's future business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company's filings with the U.S. Securities and Exchange Commission for additional information and a presentation of the risks and uncertainties that may affect the company's business and results of operations.

Contact Information: digiMedical Solutions, Inc. Investor Relations 214-722-3029